The US regulator has cleared Miplyffa (arimoclomol), in combination with the enzyme inhibitor miglustat, to treat neurological symptoms in adults and children two years of age and older with ...

Some of the patients in the study, but not all, were already being treated with miglustat. Treatment with Aqneursa achieved better scores on the SARA scale measuring gait, sitting, stance and ...